Blau Farmacêutica S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 01, 2022 at 10:54 pm
Share
Blau Farmacêutica S.A. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was BRL 365.24 million compared to BRL 370.76 million a year ago. Net income was BRL 112.4 million compared to BRL 99.49 million a year ago. Basic earnings per share from continuing operations was BRL 0.63 compared to BRL 0.56 a year ago. Diluted earnings per share from continuing operations was BRL 0.63 compared to BRL 0.56 a year ago.
For the six months, sales was BRL 678.58 million compared to BRL 696.89 million a year ago. Net income was BRL 173.86 million compared to BRL 185.66 million a year ago. Basic earnings per share from continuing operations was BRL 0.97 compared to BRL 1.14 a year ago. Diluted earnings per share from continuing operations was BRL 0.97 compared to BRL 1.14 a year ago.
Blau Farmaceutica SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The Company operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
BLAU FARMACÊUTICA S.A. 
